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Abstract Synchronous bilateral malignancy in the
parotid glands is extremely rare. The English literature
reveals nine case reports. The most common synchronous
bilateral malignancies are acinic cell carcinoma. Epithelial–
myoepithelial carcinoma is an uncommon neoplasm com-
prising 1% of all salivary gland tumours. In this case report,
we describe, to our best of knowledge, the Wrst case of a
patient with a synchronous bilateral epithelial–myoepithe-
lial carcinoma of the parotid gland. The clinical histopa-
thological and immunohistochemical peculiarities are
elucidated. Imaging studies like ultrasonography are man-
datory for both parotid glands and upper necks in the clini-
cal presence of a unilateral parotid gland tumour.
Keywords Parotid gland · Epithelial–myoepithelial 
carcinoma · Bilateral · Synchronous
Introduction
Multiple primary tumours of the parotid gland may occur
unilaterally, bilaterally, or less commonly, the combination
of bilateral primary parotid gland tumour with unilateral
multifocal parotid gland tumours. The tumours may show
identical or diVerent histology and may present synchro-
nously or metachronously [1]. The occurrence of these mul-
tiple primary parotid gland tumours is low and is reported
between 1.7 and 5% of all parotid gland tumours [2–4].
Incidences of bilateral parotid gland tumours are even
lower and occur between 1.3 and 3.5% [2–5]. Warthin
tumour is the most common bilateral parotid gland tumour
and accounts for about 85% of all cases [2, 4].
Malignant bilateral primary parotid gland tumours are
rare. Synchronous bilateral parotid gland tumours are
extremely rare. Nine cases were found at literature search in
the databases Pubmed and Medline using the following
Mesh headings: Parotid Neoplasms and Neoplasms, Multi-
ple Primary. The majority of cases are acinic cell carcinoma
(Table 1). To the best of our knowledge, we report the Wrst
patient with a synchronous bilateral epithelial–myoepithe-
lial carcinoma of the parotid glands.
Case report
Clinical course
A 40-year-old male had noticed a slowly growing painless
mass in the left pre-auricular area in the past 4 years; there
where no additional complaints. Ultrasonography (US) of
the left parotid region and neck and computed tomography
(CT) of the head and neck revealed a cystic lesion with a
diameter of 2 cm within the left parotid gland; there where
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excised via a superWcial parotidectomy approach in a
regional hospital. The histology showed an epithelial–myo-
epithelial carcinoma with extension in the resection mar-
gins. The patient was referred to the University Hospital
Maastricht for postoperative radiotherapy. The past medical
history revealed asthma and excision of a pleomorphic ade-
noma in the left parotid gland 12 years before.
On clinical examination at the Multidisciplinary Head
and Neck Outpatient Clinic, the left parotid region showed
a pre- and infra-auricular scar, concordant with a standard
approach for parotidectomy. There was mild impairment of
function of the marginal branch of the facial nerve and hyp-
oaesthesia of the skin in the parotid area and auricle, sup-
plied by branches of the greater auricular nerve. The right
parotid gland showed no palpable abnormalities. The multi-
disciplinary work-up before the initial planned postopera-
tive radiotherapy included a routine US study of the parotid
regions and entire neck, which revealed in the right parotid
gland two nodular lesions: posterior deep of 0.4 cm and
anterior superWcial of 0.7 x 0.4 cm diameter, respectively.
There was no additional pathology in the neck. US-guided
Wne-needle aspiration cytology of the two lesions within the
right parotid gland revealed a malignant lesion, probably a
muco-epidermoid carcinoma, situated posterior deep in the
parotid gland. The other anterior superWcial lesion revealed
no malignancy.
MRI demonstrated exclusively postoperative eVects in
the left parotid region. However, the two nodular lesions in
the right parotid gland were conWrmed (Fig. 1). PET-CT
imaging showed a slightly higher signal in the mediasti-
num, but this was not considered suspect for metastasis.
Full blood count, liver and kidney function tests, electro-
lytes and chest X-ray were all normal.
The Head and Neck Tumour Board advised to perform a
bilateral radical parotidectomy with selective neck dissec-
tion of Levels II and III with frozen section evaluation
eventually followed by extension to a modiWed radical neck
dissection in the presence of metastasis, followed by
bilateral postoperative radiotherapy. The patient and his
wife were carefully counselled and consent for the pro-
posed treatment was obtained. The total parotidectomy on
the right side was performed by standard retrograde facial
nerve approach, preceded by selective neck dissection of
Levels II and III. Frozen section analysis of the neck dis-
section specimen revealed no metastasis.
At surgical exploration of the left parotid region and
neck, it was not possible to identify the facial nerve stem
directly due to abundant Wbrous scar tissue. Therefore, an
ante grade approach by dissection from the peripheral
branches was chosen and a total parotidectomy performed
with anatomical preservation of facial nerve branches and
facial nerve stem. Frozen section analysis of the left selec-
tive neck dissection specimen of Levels II and III also
revealed no metastasis. Postoperatively, there was only
mild neuropraxia on the left side, which recovered com-
pletely. The preoperative existing mild dysfunction of the
mandibular branch persisted. Based on the histopatholo-
gical Wndings of a marginal radical resection of the remain-
ing tumour in the left parotid gland and the radically
excised tumour of the right parotid gland, postoperative
radiotherapy was indicated for the left side only. This was
performed 3 weeks after the last surgery. The schedule was
as follows; the parotid region received 70 Gy and the left
side of the neck received 50 Gy, both given in fractions of
2 Gy, Wve times a week. Psychologic support was given for
a 1-year period. Four years postoperative, there are no sings
of recurrence. The symptoms of Frey syndrome were suc-
cessfully treated with Botox injections.
Material and methods
The surgical specimens were Wxed in formalin. Two- to
three-m-thick sections for histological examination were
routinely processed in paraYn and stained with haematoxy-
lin and eosin. For immuno-histochemical studies, represen-
tative sections were evaluated using the avidin–biotin–
Table 1 Synchronous bilateral 
parotid gland carcinoma Author Age Sex Histology
Bauer and Bauer (1953) [6] 65 M Acinic cell carcinoma
Diamant et al. (1961) [7] 71 M Acinic cell carcinoma
55 M Acinic cell carcinoma
Clarke et al. (1969) [8] 57 F Acinic cell carcinoma
Levin et al. (1975) [9] 57 F Acinic cell carcinoma
Delides et al. (2005) [10] 64 M Acinic cell carcinoma
Berkeley (1959) [11] 5 M Adenocarcinoma
Ferlito (1978) [12] 67 M Adenocarcimoma
Hakuba et al. (2003) [13] 48 M Mucoepidermoid carcinoma
van Tongeren et al. (2008) [This study] 40 M Epithelial–myoepithelial carcinoma123
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and negative controls. The immuno-histochemical panel
contained antibodies against pankeratin (clone MNF116,
1:500, DAKO), S100 protein (1:5,000, DAKO) and Alfa
smooth muscle actin (clone 1A4, 1:1000, Sigma), p63
(Clone 4A4, DAKO).
For mutation analysis in the DNA-binding domain of the
p53 gene (exons 5–8), genomic DNA was extracted and
analysed by single-strand conformation polymorphism
(SSCP). ParaYn-embedded tissue sections (3 £ 10 m) of
each tumour were deparaYnised by xylene and dehydrated
with 100% ethanol. DNA was isolated by the DNA Pure-
gene isolation kit (Biozym) and DNA fragments compris-
ing exons 5–8 of the p53 gene were ampliWed by
polymerase chain reaction (PCR) using primers as
described previously [14]. A standard PCR reaction in
20 l with a Wnal concentration of 3 mM MgCl2 was per-
formed (35 cycles, annealing temperature 60°C). PCR
products were denatured and separated on a nondenaturat-
ing 10% polyacrylamide gel at 40 W for 3 h at 12°C and
analysed by silver staining.
Pathological Wndings
The resection of the right parotid gland revealed a relatively
well-circumscribed tumour measuring 0.4 cm in maximum
dimension, radically excised with margins more than
0.6 cm. Twenty-two lymph nodes revealed no metastases.
In the remaining left parotid gland tissue, a radical-removed
tumour of 0.2 cm in diameter was discovered with a margin
of 0.1 cm. Nineteen lymph nodes showed no metastases.
The histological examination of the tumours in the left
and right parotid glands showed a similar appearance. The
tumours were moderately circumscribed and a thin Wbrous
connective tissue capsule separates the tumour from the
normal parotid gland parenchyma (Fig. 2a). Focally, nests
of tumour cells inWltrate the adjacent parotid parenchyma
(Fig. 2b). It is composed of ductal elements surrounded by
clear cells (Fig. 2c). The epithelial ductal component is
arranged in sheets and nests. The ductal cells are Xat to
cuboidal with a light eosinophilic cytoplasm and a round to
oval central placed nucleus. The ductal cells are immuno-
reactive for pankeratin (MNF 116) (Fig. 2d). The myoepi-
thelial cells are more variable in size than the ductal cells
and have variable amounts of clear or light eosinophilic
cytoplasm. They are mostly elongated or spindle-shaped.
Immunoreactivity for S100 (Fig. 2e) and Alfa smooth mus-
cle actin is intense in the clear myoepithelial cells. Both
tumours demonstrate a very strong p63 nuclear staining in
the “abluminal” clear myoepithelial cells (Fig. 3). As a pos-
itive intern control p63 reactive nuclei were seen in the
basal cells of the interlobular ducts and some small-elon-
gated nuclei at the periphery of the acini. The acini as well
the luminal cells are negative for p63. The cytological aty-
pia is mild to moderate (data not shown). The tumours
showed a low mitotic rate (1 MF/2 mm2) (Fig. 2c).
Fig. 1 Axial SE T1-weighted images of the neck showing on the right
side (a) in the upper part of the superWcial lobe of the parotid gland a
small and not well circumscribed lesion (arrow). On the left side (b) in
the deep lobe of the parotid gland a hyper-intense region can be appre-
ciated (arrow) besides the hypo-intense postoperative changes in the
superWcial lobe (arrowheads)123
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mutation), tumour specimens were analyzed by single-
strand conWrmation polymorphism (SSCP). After extrac-
tion of DNA from both samples, the exons were ampliWed
separately. PCR products were separated by SSCP analysis
at two temperatures. After silver staining, no mutation in
exons 5, 6, 7 or 8 of the P53 gene was detected in both
tumours.
Discussion
Synchronous bilateral malignant parotid gland tumours are
extremely rare. Until now six cases of acinic cell carcinoma,
two cases of adenocarcinoma and one case of mucoepider-
moid carcinoma have been reported in the English litera-
ture. Although Medline and Pubmed are excellent sources
of the present literature on this subject, they are known to
be incomplete and we may have missed important abstracts
or reports. To our best knowledge, this case report is the
Wrst description of a synchronous bilateral epithelial–myo-
epithelial carcinoma of the parotid gland.
Epithelial–myoepithelial carcinoma (EMC) is an uncom-
mon epithelial neoplasm, comprising approximately 1% of
all salivary gland tumours. Therefore, we choose to elabo-
rate into this particular tumour.
The tumour is mainly composed of variable portions of
ductal and clear staining myoepithelial cells. EMC is
Fig. 2 a Overview of the tumour separated from the normal parotid
gland tissue by a thin Wbrous pseudo capsule (£2.5, Ø 9 mm). b Focal-
ly, nests of tumour cells inWltrate the adjacent normal parotid gland
(£20, Ø 1 mm). c The tumour is composed of ductal epithelial cells
(arrowhead) and clear myoepithelial cells (asterisk) (HE £40, Ø
0.5 mm); mitotic Wgures are seen (arrows). d The MNF116 stains
strongly the ductal epithelial component (£40, Ø 0.5 mm). e The clear
myoepithelial cells show strong S100 immunoreactivity (£20, Ø
1 mm)123
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cially the parotid gland, but they may also arise in minor
salivary glands [15–17] and rarely in extra-oral sites such
as the paranasal sinuses [15, 16], pharynx [16] and bron-
chus [18]. Tumours with similar histological features to
EMC of the salivary gland have been identiWed in breast
and skin [19, 20]. EMC is primarily a tumour of adults,
although tumours in children have been reported [21]. The
peak incidence is in the seventh decade of life; the mean
age of patients is about 60 years. About 60% of the patients
are female. In 1982, Corio et al. reported the largest series
of 16 cases in the English literature [22].
The term epithelial–myoepithelial carcinoma was intro-
duced in 1972 by Donath et al. [23]. This neoplasm was
formerly referred to as a clear cell adenoma and adeno-
myoepithelioma [22, 24].
Because of the tendency to local recurrence and the low
metastatic potential, the tumour is now recognised to be a
low-grade malignant tumour in the WHO salivary gland
classiWcation. In 2001, Deere et al. reported a signiWcant
local recurrence rate of 42% in patients with EMC of the
salivary glands [25]. The same authors reported in 10% of
the cases metastases, especially to the periparotid and cervi-
cal lymph nodes. Rare EMC might show a very aggressive
behaviour with distant metastasis [24, 26]. For many
authors, a complete surgical resection is the only and best
treatment for EMC. Deere et al. reported that adjuvant
radiotherapy might be eVective in preventing local recur-
rence [25].
A typical EMC is histologically composed of a classical
double (biphasic) cell lining of smaller inner ductal cells
and outer larger clear myoepithelial cells. Immuno-
histologically, the ductal cells are positive for MNF116
pankeratin and the myoepithelial cells are strongly reactive
for the common myoepithelial markers ASMA and S100,
but negative for MNF116 pankeratin. The myoepithelial
component also shows a strong nuclear staining for p63
(Fig. 2c).
The anti-p63 antibody is a selective immuno-histo-
chemical marker staining the nuclei of basal (progenitor/
stem) cells of stratiWed epithelium, like skin, the mucosa
of the oral cavity, oesophagus, cervix and urothelium
[27]. p63 immunoreactivity has been demonstrated in
squamous cell and urothelial cells, and is absent in most
non-squamous carcinomas [27, 28]. Research has shown
that the anti-p63 antibody is a good marker of myoepithe-
lial cells with sensitivity comparable to other myoepithe-
lial markers, like ASMA and calponin, but also with a
higher speciWcity [29]. To date only a few studies on the
expression of p63 in salivary gland tumours have been
published [27, 29–32]. p63 immuno-histochemistry is
only described in two EMCs, also showing a strong
nuclear staining of the clear myoepithelial cells [31]. The
strong positivity for p63 in our bilateral parotid gland
tumour suggests that p63 is up-regulated and that the neo-
plastic myoepithelium is a key cellular participant in the
morphogenesis of EMC. The exact origin of EMC is not
clear. Corio et al. considered the EMC to arise from the
intercalated ducts [22].
Recently, immunohistochemical positivity for CD117
[33, 34] and Bcl 2 [33] was described in EMC. Furuse et al.
studied immunohistochemical beta-catenin expression in
salivary gland tumours (pleiomorphic adenoma, adenoid
cystic carcinoma, polymorphous low-grade adenocarci-
noma and EMC) and showed a striking diVuse beta-catenin
nuclear positivity in the myoepithelial cell component of
the EMC [35].
In the present case report, all histological examinations
were similar for both tumours. Surgery is the treatment of
choice and to ensure adequate removal, a subtotal or total
parotidectomy is recommended, followed by radiotherapy.
The fact that, in the left parotid gland, 12 years earlier, a
benign tumour was diagnosed and later followed by a
malignant tumour makes this case unique. The present
report also illustrates that a pre-operative work up of
patients with clinically a unilateral parotid gland tumour
should include imaging studies like US to exclude occult
contra-lateral disease. Post-operative follow-up of patients
with a unilateral parotid gland tumour should always
include investigation of the contra-lateral parotid gland, as
bilateral tumour can occur metachronously.
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Fig. 3 The myoepithelial component shows also a strong nuclear
staining for p63123
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